The FDA issued an untitled letter to Evolus on September 28 regarding an Instagram reel promoting Jeuveau, the company’s tox offering, as reported by Fierce Pharma. The agency cited two main violations:
- Downplaying Risks: The reel’s caption claimed Evolus is “blurring the lines between what’s found in your beauty bag and what happens in the treatment room” (accompanied by syringe and lipstick emojis). The FDA stated that comparing a prescription neurotoxin with a boxed warning to an everyday cosmetic like lipstick minimizes its serious health risks.
- Misleading Efficacy Claims: The reel claimed Jeuveau gets “rid of” frown lines and works “in as little as 2 days.” The FDA pointed out that Jeuveau is only approved for temporary improvement, and that the 2-day timeline relies on exploratory endpoints rather than primary clinical trial data, creating a false impression.
Evolus was given 15 working days to respond. The warning challenges Evolus’ long-held corporate strategy of branding Jeuveau strictly as an “edgy” consumer beauty brand.
The Instagram reel featured the caption, “blurring the lines between what’s found in your beauty bag and what happens in the treatment room,” accompanied by syringe and lipstick emojis. FDA officials called this comparison “especially problematic,” explaining that framing Jeuveau like a typical beauty product implies it can be seamlessly integrated into a standard cosmetic routine—like keeping a lipstick in a makeup bag—which dangerously downplays the serious medical risks involved. Treating a prescription neurotoxin as an everyday cosmetic conflicts with Evolus’ consumer-first marketing strategy, which CEO David Moatazedi has previously highlighted as driven by creative teams outside healthcare to build an “edgy,” beauty-focused brand.
Additionally, the FDA challenged claims made in the post regarding the onset and magnitude of Jeuveau’s effects. The reel featured a video participant celebrating “getting rid of” her lines, alongside text stating, “Lines today. Blurred in as little as 2 days.” The agency noted that Jeuveau is strictly approved for the temporary improvement of frown lines, and that complete elimination of lines was only an exploratory endpoint in clinical trials. Furthermore, because efficacy at Day 2 was also measured as an exploratory endpoint—unlike the primary endpoint evaluated at Day 30—the claims present a misleading picture of how fast and reliably the treatment works. Evolus has 15 working days from receipt of the letter to submit a response to the FDA.
As of this posting, Evolus has not yet provided a response.
Leave a Reply